之江生物拟6000万元至1.2亿元回购股份，公司股价年内涨37.85%

Core Viewpoint - Zhijiang Bio plans to repurchase shares through centralized bidding, with a total amount between 60 million and 120 million yuan, and a maximum repurchase price of 37.99 yuan per share, which is 69.60% higher than the current price of 22.40 yuan [1] Group 1: Share Repurchase Details - The repurchase period is set for 12 months, and the funding will come from self-owned and self-raised funds [1] - This marks the third share repurchase announcement by the company this year, with the previous repurchase occurring on April 30, 2025, at a maximum price of 25.05 yuan per share [1] - Since the last announcement, the company has repurchased 5.8295 million shares, totaling approximately 110 million yuan, with a price increase of 38.02% during that period [1] Group 2: Company Overview - Zhijiang Bio, established on April 18, 2005, and listed on January 18, 2021, specializes in the research, production, and sales of molecular diagnostic reagents and equipment [2] - The company's main revenue sources are 86.47% from nucleic acid testing kits, 11.99% from other products, and 1.54% from molecular diagnostic instruments [2] - As of June 30, 2025, the company had 15,600 shareholders, a decrease of 1.17%, with an average of 12,281 circulating shares per person, an increase of 1.19% [2] Group 3: Financial Performance - For the first half of 2025, Zhijiang Bio reported a revenue of 59.6831 million yuan, a year-on-year decrease of 36.91%, and a net profit attributable to shareholders of -9.851 million yuan, a decrease of 137.88% [2] - The company has distributed a total of 829 million yuan in dividends since its A-share listing, with 251 million yuan distributed over the past three years [3] Group 4: Institutional Holdings - As of June 30, 2025, the top ten circulating shareholders include Guangfa Value Core Mixed A, holding 4.8172 million shares, and Rongtong Health Industry Flexible Allocation Mixed A/B, holding 1.5 million shares, both unchanged from the previous period [3]